Dew, have you ever heard of this company before, Oncologie? Their website looks like it was made with crayons and not a single link works. This feels like a scam.
$8M + contingencies is a pretty good price for a placebo-like drug. This may be the shrewdest business transaction CDMO/PPHM has ever made.
They acquired the patent rights to target PS for $8M and will continue development with NCCN. Unless they have determined that patents will not hold up in court, this is a bad deal for shareholders. There are many BP’s now that are investigating and targeting phosphatidylserine with their own drugs.